CN111329973A - Isuzkak extract and preparation method and application thereof - Google Patents

Isuzkak extract and preparation method and application thereof Download PDF

Info

Publication number
CN111329973A
CN111329973A CN202010285248.2A CN202010285248A CN111329973A CN 111329973 A CN111329973 A CN 111329973A CN 202010285248 A CN202010285248 A CN 202010285248A CN 111329973 A CN111329973 A CN 111329973A
Authority
CN
China
Prior art keywords
extract
italian
alcohol
water
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010285248.2A
Other languages
Chinese (zh)
Inventor
阿地力江·伊明
阿卜杜热伊木·如则
木合布力·阿布力孜
毛吾兰·买买提依明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinjiang Medical University
Original Assignee
Xinjiang Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinjiang Medical University filed Critical Xinjiang Medical University
Priority to CN202010285248.2A priority Critical patent/CN111329973A/en
Publication of CN111329973A publication Critical patent/CN111329973A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9062—Alpinia, e.g. red ginger or galangal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides an Italian saxaka extract and a preparation method and application thereof, belonging to the technical field of medicine purification. According to the invention, the active ingredients can be extracted by carrying out alcohol reflux extraction and water boiling extraction on the mixture powder prepared from 8 ingredients except the bull penis, the musk and the ambergris in the Italian saxophone, so that the impurity ingredients in the medicine can be reduced; by mixing the ethanol extract powder and the water extract powder with the bull penis, the musk and the ambergris, the efficacy of the obtained Italian saxophone extract is basically the same as that of the Italian saxophone tablet, but the drug dosage is obviously reduced. The results of the examples show that the administration dose of the Italian saxak extract of the invention is reduced by 65.37% compared with the administration dose of the commercially available Italian saxak tablets; from the key index of the number of times of rat insertions, the therapeutic effect of the Italian saxak extract is 92.41% of that of the commercially available Italian saxak tablet, which indicates that the efficacy of the Italian saxak extract is substantially the same as that of the commercially available Italian saxak tablet.

Description

Isuzkak extract and preparation method and application thereof
Technical Field
The invention relates to the technical field of medicine purification, and particularly relates to an Italian saxaka extract and a preparation method and application thereof.
Background
Yimuzake is a medicine for invigorating kidney, strengthening Yang, replenishing vital essence and arresting discharge, and is used in treating impotence, premature ejaculation, spermatorrhea, enuresis and neurasthenia. The Yimuzake is prepared from 11 Chinese medicinal materials (Olibanum, testis Et penis bovis seu Bubali, rhizoma Alpiniae Officinarum, semen Strychni, Moschus, LONGJIXIANG, flos Caryophylli, plantula Papaveris, stigma croci Sativi, semen Myristicae, and rhizoma Bletillae), by decocting plantula Papaveris in water, pulverizing, sieving, mixing directly, and making into tablet. The preparation method is simple, and has the problems of more ineffective components such as cellulose, polysaccharide, tannin, etc., and undefined active ingredients. In addition, the traditional tablet has more ineffective components, so that the dosage of the traditional tablet for one time is larger (about 1.5 grams).
Disclosure of Invention
In view of the above, the present invention aims to provide an imossac extract, a preparation method and applications thereof. The preparation method provided by the invention can extract the active ingredients of clove, bletilla striata, poppy shell, nutmeg, frankincense, nux vomica, galangal and saffron in the Italian sago, the obtained active ingredients of the Italian sago extract are clear, and the medicine dosage can be effectively reduced on the basis of not influencing the medicine effect.
In order to achieve the purpose of the invention, the invention provides the following technical scheme:
the invention provides a preparation method of an Italian saxaka extract, which comprises the following steps:
(1) mixing flos Caryophylli, rhizoma Bletillae, plantula Papaveris, semen Myristicae, Olibanum, semen Strychni, rhizoma Alpiniae Officinarum and stigma croci Sativi according to their prescription amount in IMUXACAKE, pulverizing, and sieving to obtain mixture powder;
(2) carrying out alcohol reflux extraction on the mixture powder to obtain an alcohol extract and alcohol extract dregs;
(3) sequentially carrying out first concentration, first freeze drying and second crushing and sieving on the alcohol extract to obtain alcohol extract powder;
(4) decocting the alcohol extract dregs in water to obtain water extract extractum and water extract dregs;
(5) sequentially carrying out second concentration, second freeze drying, third crushing and sieving on the water extract to obtain water extract powder;
(6) mixing the ethanol extract powder and the water extract powder with penis et testis bovis seu Bubali, Moschus, and ambergris to obtain an Italian Sak extract; the dosages of the bullwhip, the musk and the ambergris are the amounts of the bullwhip, the musk and the ambergris in the Italian saxophone;
the step (3) and the steps (4) and (5) have no requirement of time sequence.
Preferably, the particle size of the mixture powder is less than or equal to 250 mu m.
Preferably, the alcohol extracting agent used in the alcohol reflux extraction in the step (2) is an ethanol solution, and the volume fraction of the ethanol solution is 60%; the mass ratio of the mixture powder to the ethanol solution is 1: 8-10;
the temperature of the alcohol reflux extraction is 100-110 ℃; the reflux extraction times of the alcohol are 2-3 times; the time of single alcohol reflux extraction is 2-3 h.
Preferably, the first concentration in the step (3) is reduced pressure concentration, the pressure of the reduced pressure concentration is 0.085-0.095 Mpa, and the time is 8-10 hours;
the temperature of the first freeze drying is-40 ℃, and the time is 48-54 h;
the particle size of the alcohol extract powder is 150-250 mu m.
Preferably, the mass ratio of the alcohol extract dregs to the water in the water boiling in the step (4) is 1: 8-10; the boiling temperature is 95-100 ℃;
the number of times of water boiling is 2-3, and the time of single water boiling is 2-3 h.
Preferably, the second concentration in the step (5) is reduced pressure concentration, the pressure of the reduced pressure concentration is 0.085-0.095 Mpa, and the time is 8-10 hours;
the temperature of the second freeze drying is-40 ℃, and the time is 48-54 h;
the particle size of the water extract powder is less than or equal to 250 mu m.
Preferably, the particle sizes of the bullwhip, the musk and the ambergris in the step (6) are independently less than or equal to 250 microns.
The invention provides the Italian saxak extract prepared by the preparation method, wherein the active ingredients in the Italian saxak extract comprise total polysaccharides, total saponins, total alkaloids and total flavonoids.
Preferably, the total polysaccharide accounts for 25.74-26.26% by mass of the Isuzkak extract;
the mass percentage of the total saponins in the Isuzkak extract is 21.71-22.13%;
the mass percentage of the total alkaloids in the Isuzkake extract is 17.92-18.28%;
the mass percentage of the total flavone in the Isuzkak extract is 21.53-21.96%.
The invention provides an application of the Italian saxak extract in preparing an Italian saxak medicine.
The invention provides a preparation method of an Italian saxak extract, which comprises the steps of sequentially carrying out alcohol reflux extraction and water boiling extraction on mixture powder prepared from 8 components except bullwhip, musk and ambergris in the Italian saxak to obtain alcohol extract powder and water extract powder, wherein active ingredients can be extracted, and impurity components in medicaments are reduced; by mixing the ethanol extract powder and the water extract powder with the bull penis, the musk and the ambergris, the efficacy of the obtained Italian saxak extract is basically the same as that of the commercially available Italian saxak tablet, but the drug dosage is obviously reduced. The results of the examples show that the administration dosage of the obtained Italian saxaka extract is reduced by 65.37% compared with the administration dosage of the commercially available Italian saxaka tablets; from the key index of the number of times of rat insertions, the therapeutic effect of the Italian saxak extract is 92.41% of that of the commercially available Italian saxak tablet, which indicates that the drug effect of the Italian saxak extract is substantially the same as that of the commercially available Italian saxak tablet.
Detailed Description
The invention provides a preparation method of an Italian saxaka extract, which comprises the following steps:
(1) mixing flos Caryophylli, rhizoma Bletillae, plantula Papaveris, semen Myristicae, Olibanum, semen Strychni, rhizoma Alpiniae Officinarum and stigma croci Sativi according to their prescription amount in IMUXACAKE, pulverizing, and sieving to obtain mixture powder;
(2) carrying out alcohol reflux extraction on the mixture powder to obtain an alcohol extract and alcohol extract dregs;
(3) sequentially carrying out first concentration, first freeze drying and second crushing and sieving on the alcohol extract to obtain alcohol extract powder;
(4) decocting the alcohol extract dregs in water to obtain water extract extractum and water extract dregs;
(5) sequentially carrying out second concentration, second freeze drying, third crushing and sieving on the water extract to obtain water extract powder;
(6) mixing the ethanol extract powder and the water extract powder with penis et testis bovis seu Bubali, Moschus, and ambergris to obtain an Italian Sak extract; the dosages of the bullwhip, the musk and the ambergris are the amounts of the bullwhip, the musk and the ambergris in the Italian saxophone;
the step (3) and the steps (4) and (5) have no requirement of time sequence.
The invention mixes clove, bletilla striata, poppy shell, nutmeg, frankincense, nux vomica, galangal and saffron according to the prescription amount of the components in the Yimuzak, and then the mixture powder is obtained by first crushing and sieving. In the present invention, the prescribed amounts of clove, bletilla striata, poppy shell, nutmeg, frankincense, nux vomica, galangal and saffron in imazak are preferably as shown in table 1:
TABLE 1 prescription of eight herbs involved in extraction
Figure BDA0002448245870000041
In the present invention, the mixing is preferably performed by stirring; the invention preferably uses a pulverizer to stir and mix, and the stirring speed is preferably 3000-3500 r/min, more preferably 3200-3400 r/min; the stirring time is preferably 2-3 min, and more preferably 2.5 min. In the invention, the first crushing and sieving is preferably a sieve of 150-250 μm. In the present invention, the particle diameter of the mixture powder is preferably 250 μm or less, more preferably 150 μm or less.
After the mixture powder is obtained, the invention carries out alcohol reflux extraction on the mixture powder to obtain alcohol extract extractum and alcohol extract dregs. In the present invention, the extractant for alcohol reflux extraction is an ethanol solution, and the volume fraction of the ethanol solution is preferably 60%. In the invention, the mass ratio of the mixture powder to the ethanol solution in the alcohol reflux extraction is preferably 1: 8-10, and more preferably 1: 9; the temperature of the alcohol reflux extraction is preferably 100-110 ℃, and more preferably 105 ℃. In the invention, the reflux extraction of the alcohol is preferably performed for 2-3 times, and more preferably for 2 times; the time of single alcohol reflux extraction is preferably 2-3 h, and more preferably 2.5 h; the invention preferably combines the extracts obtained after the two times of alcohol reflux extraction to obtain the alcohol extract.
After the alcohol extract is obtained, the alcohol extract is subjected to first concentration, first freeze drying, second crushing and sieving in sequence to obtain alcohol extract powder. In the invention, the first concentration mode is preferably reduced pressure concentration, and the pressure of the reduced pressure concentration is preferably 0.085-0.095 MPa, and more preferably 0.09 MPa; the time is preferably 8-10 h, and more preferably 9 h. In the invention, the temperature of the first freeze drying is preferably-40 ℃, and more preferably-20 ℃; the time is preferably 48 to 54 hours, and more preferably 50 to 52 hours. In the invention, the second crushing and sieving is preferably a sieve with the particle size of 150-250 μm. In the present invention, the particle size of the alcohol extract powder is preferably 250 μm or less, more preferably 150 μm or less.
After the alcohol extract dregs are obtained, the invention boils the alcohol extract dregs in water to obtain water extract extractum and water extract dregs. In the invention, the mass ratio of the alcohol extract dregs to water in the water boiling process is preferably 1: 8-10, and more preferably 1: 9; the water boiling temperature is preferably 95-100 ℃, and more preferably 96-98 ℃; in the invention, the number of times of water boiling is preferably 2-3 times, and more preferably 2 times; the time of single water boiling is preferably 2-3 h, and more preferably 2.5 h; the invention preferably mixes the water extracts obtained after two times of water boiling to obtain the water extract. In the present invention, the inactive ingredients of the mixture powder are present in the aqueous extract residue.
After obtaining the water extract, the invention sequentially carries out second concentration, second freeze drying, third crushing and sieving on the water extract to obtain water extract powder. In the invention, the second concentration mode is preferably reduced pressure concentration, and the pressure of the reduced pressure concentration is preferably 0.085-0.095 MPa, and more preferably 0.09 MPa; the time is preferably 8-10 h, and more preferably 9 h. In the invention, the temperature of the second freeze drying is preferably-40 ℃, and more preferably-20 ℃; the time is preferably 48 to 54 hours, and more preferably 50 to 52 hours. In the invention, the third crushing and sieving is preferably a sieve of 150-250 μm. In the present invention, the particle size of the aqueous extract powder is preferably 250 μm or less, more preferably 150 μm or less.
After the alcohol extract powder and the water extract powder are obtained, the alcohol extract powder and the water extract powder are mixed with the bull penis, the musk and the ambergris to obtain the Italian saxophone extract. The bullwhip, musk and ambergris are used according to the prescription in the Italian saxophone. In the present invention, the prescribed amounts of the bull's penis, musk and ambergris in imazakh are preferably as shown in table 2:
TABLE 2 prescription of bull penis, Musk and ambergris
Figure BDA0002448245870000051
In the invention, the particle sizes of the bullwhip, the musk and the ambergris are independently and preferably 150-250 μm, and more preferably 200 μm. The mixing mode of the alcohol extract powder, the water extract powder, the bull penis, the musk and the ambergris is preferably stirring and mixing; the invention preferably uses a pulverizer to stir and mix, and the stirring speed is preferably 3000-3500 r/min, more preferably 3200-3400 r/min; the stirring time is preferably 2-3 min, and more preferably 2.5 min.
After the Italian saxak extract is obtained, the Italian saxak extract is preferably compressed into tablets. The process of the present invention for compressing into tablets is not particularly critical and compression methods well known to those skilled in the art may be used.
The invention provides the Italian saxak extract prepared by the preparation method, wherein the active ingredients in the Italian saxak extract comprise total polysaccharides, total saponins, total alkaloids and total flavonoids.
In the invention, the mass percentage of the total polysaccharide in the Isuzkak extract is preferably 25.74-26.26%, and more preferably 26%; the mass percentage of the total saponins in the Isuzkak extract is 21.71-22.13%, and the mass percentage of the total saponins in the Isuzkak extract is more preferably 21.92%; the mass percentage content of the total alkaloids in the Isuzkake extract is preferably 17.92-18.28%, and more preferably 18.1%; the mass percentage of the total flavone in the Isuzkak extract is preferably 21.53-21.96%, and more preferably 21.75%.
The Isuzumab extract provided by the invention has definite active ingredients, and can effectively reduce the drug dosage on the basis of not influencing the drug effect.
The invention also provides application of the Italian saxak extract in preparation of Italian saxak drugs.
The present invention will be described in detail with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
(1) Mixing clove, bletilla striata, poppy shell, nutmeg, frankincense, nux vomica, galangal and saffron according to the formula dosage of the Italian saxophone, and crushing and sieving the mixture to obtain mixture powder with the particle size of 150-250 mu m. The formula amounts of the eight medicinal materials are shown in table 1.
(2) Performing ethanol solution reflux extraction on the mixture powder, wherein the volume fraction of the ethanol solution is 60%, and the mass ratio of the mixture powder to the ethanol solution is 1: 9; refluxing at 100 deg.C for 2 times (each for 2 hr), mixing the extracts obtained by two times of alcohol reflux extraction to obtain alcohol extract, and mixing the residues to obtain alcohol extract residue.
(3) Concentrating the alcohol extract under 0.085MPa for 8h, freeze-drying at-40 ℃ for 48h, crushing and sieving to obtain alcohol extract powder with the particle size of 150-250 mu m, and weighing the alcohol extract powder to obtain 550g of alcohol extract powder.
(3) Decocting the alcohol extract dregs twice in water at 100 ℃, wherein the water decocting time is 2 hours each time, and the mass ratio of the alcohol extract dregs to the water is 1:10 each time; and mixing the water extracts obtained after the two times of water boiling to obtain an aqueous extract.
(4) Concentrating the water extract for 8h under 0.085MPa, freeze-drying for 48h at-40 ℃, crushing and sieving to obtain water extract powder with the particle size of 150-250 mu m, and weighing the water extract powder to obtain 151g of water extract powder.
(5) Mixing the ethanol extract powder and water extract powder with penis et testis bovis seu Bubali, Moschus, and ambergris to obtain Iwood Sak extract; wherein the addition amounts of penis Et testis bovis Seu Bubali, Moschus, and ambergris are shown in Table 2.
The cream yield of the alcohol extract powder is calculated according to the formula I, and the cream yield of the alcohol extract powder by the method is 19.84 percent by calculation.
RAlcohol(s)＝mAlcohol(s)/mGeneral assembly× 100% of formula I;
in the formula I, RAlcohol(s)The percentage of the extract of the alcohol extract powder is;
malcohol(s)The mass of the alcohol extract powder, g;
mgeneral assemblyIs the total mass of clove, bletilla striata, poppy shell, nutmeg, frankincense, nux vomica, galangal and saffron, g.
The cream yield of the alcohol extract powder was calculated according to formula II, and by calculation, the cream yield of the water extract powder by the method of the present invention was 5.45%.
RWater (W)＝mWater (W)/mGeneral assembly× 100% formula II;
in the formula II, RWater (W)Is the cream yield of the aqueous extract powder,%;
Mwater (W)Mass of the aqueous extract powder, g;
mgeneral assemblyIs the total mass of clove, bletilla striata, poppy shell, nutmeg, frankincense, nux vomica, galangal and saffron, g.
The dosage of the imazak extract was calculated according to formula III, based on the dosage of 250mg/kg of the currently commercially available imazak tablet:
M＝mcomposition comprising a metal oxide and a metal oxide/mYimuzak formula×M0Formula III;
in the formula III, M is the administration dosage of the Isuzmark extract, mg/kg;
mcomposition comprising a metal oxide and a metal oxideIs the mass of the Isuzkak extract in kg;
myimuzak formulaKg, total mass of the imazak formulation;
M0the standard dose of administration, kg, was for the imazak tablet.
The administration dose of the obtained imazak extract of the present invention was calculated to be 86.575mg/kg, which was reduced by 65.37% compared to the administration dose of the commercially available imazak tablet.
Comparative example 1
Preparing mixed powder of clove, bletilla striata, poppy shell, nutmeg, frankincense, nux vomica, galangal and saffron according to the method and the dosage of the embodiment 1, adding distilled water (the volume ratio of the mixed powder to the distilled water is 1:10) into the mixed powder, and carrying out steam distillation; the steam distillation frequency is 2 times, each time distillation is 2h, 1.386g of volatile oil and residual water solution are obtained after standing and layering at room temperature, and the cream yield of the volatile oil is calculated to be 0.5%.
As can be seen from comparison between example 1 and comparative example 1, the ethanol extract powder and the water extract powder obtained by the method provided by the invention have higher cream yield.
Comparative example 2
Mixing the alcohol extract powder obtained in the example 1 with the bullwhip, the musk and the ambergris to obtain the Italian Sak alcohol extract composition, wherein the adding amount of the bullwhip, the musk and the ambergris is { the weight of the alcohol extract powder/(the weight of the alcohol extract powder + the weight of the water extract powder) } × the formula amount corresponding to each component shown in the table 2.
The dosage of the ixabepil extract composition was calculated according to formula III and was calculated to be 67.87 mg/kg.
Comparative example 3
Mixing the water extract powder obtained in the example 1 with the bullwhip, the musk and the ambergris to obtain the Italian saxak water extract composition, wherein the adding amount of the bullwhip, the musk and the ambergris is { the weight of the water extract powder/(the weight of the alcohol extract powder + the weight of the water extract powder) } × the formula amount corresponding to each component shown in the table 2.
The dosage of the aqueous extract of imazakhstan composition administered was calculated according to formula III and calculated to be 18.7 mg/kg.
Test example 1
Qualitative identification of the components of the extracts of example 1 and comparative examples 2 to 3 and the commercially available imazak tablets was performed using biuret reagent, picric acid, silicotungstic acid, potassium bismuth iodide, 3% ferric chloride solution, 5% sodium hydroxide solution, concentrated sulfuric acid, magnesium hydrochloride powder, molish reagent, fehling reagent, 1.1% ferric chloride solution, gelatin and acidimeter, and the obtained results are listed in table 3:
TABLE 3 qualitative identification of Isuzmark extracts
Figure BDA0002448245870000081
Figure BDA0002448245870000091
In Table 3, "+" indicates a positive reaction; "-" indicates a negative reaction.
According to the qualitative test results, the Isuzmark extract obtained in example 1 contains protein, alkaloid, flavone, saponin, polysaccharide, phenols, organic acid and other components; the Isuzkak alcohol extract obtained in the comparative example 2 contains components such as protein, flavone, saponin, polysaccharide, organic acid and the like; the water extract of Isuzmark obtained in comparative example 3 contains protein, alkaloid, flavonoid, saponin, polysaccharide, phenol, organic acid and other components.
Test example 2
Phenol-concentrated sulfuric acid as developer, glucose as reference, and sodium nitrite (NaNO)2) Aluminum nitrate [ Al (NO)3)3]Sodium hydroxide (NaOH) color development the total polysaccharide content of the compositions of the commercially available Italian saxophone tablets (manufacturer: and Tian Uygur pharmaceuticals Ltd., lot number: 20170702) and example 1 was determined. The total polysaccharide has good linear relation in the concentration range of 30 mu g/mL to 105 mu g/mL at the wavelength of 486nm, and the regression equation is as follows: 0.00804298x-0.0563855 (R)20.9917), the content of total polysaccharides in the Isuzmark extract is 25.74-26.26%, and the content in the Isuzmark tablet is 43.54-44.41%.
Taking vanillin-glacial acetic acid as developer, oleanolic acid as control, and sodium nitrite (NaNO)2) Aluminum nitrate [ Al (NO)3)3]Sodium hydroxide (NaOH) color development the total saponin content of the commercially available imazak tablets and the composition of example 1 was determined. The linear relation of the total saponin at 551nm in the concentration range of 80 mu g/mL to 180 mu g/mL is good, and the regression equation is as follows: 0.00338342x-0.99354 (R)20.997), the content of the saponin in the Isuzmark extract is 21.71-22.13%, and the content in the Isuzmark tablet is 17.11-17.44%.
Taking berberine hydrochloride as reference substance, and sodium nitrite (NaNO)2) Aluminum nitrate [ Al (NO)3)3]Sodium hydroxide (NaOH) color development was performed to measure the total alkaloid content in the commercially available Italian saxophone tablets and the composition of example 1. The linear relation of the total alkaloid at the wavelength of 421nm in the concentration range of 10 mu g/mL to 60 mu g/mL is good, and the regression equation is as follows: 0.0170375x-0.0389502 (R)20.999), the alkaloid content in the Italian saxak extract is 17.92-18.28%, and the alkaloid content in the Italian saxak tablet is 17.92-18.28%5.67～5.79％。
The content of total flavonoids in the commercially available Italian saxophone tablets and the composition of example 1 was measured by UV spectrophotometry using rutin as a control. The general flavone has good linear relation in the concentration range of 20 mu g/mL to 120 mu g/mL at 356nm, and the regression equation is as follows: 0.00334740x-0.00182693 (R)20.985), the content of flavone in the Isuzmark extract is 21.53-21.96%, and the content in the Isuzmark tablet is 15.79-16.09%.
Test example 3
Establishing an ED (erectile dysfunction) rat model, dynamically observing the animal model through changes of biological characteristics such as tongue coating, body weight, food intake, water intake, urine intake and stool intake, periodically evaluating the erectile function through an APO (android package) erectile experiment and a behaviour-oriented experiment, and finally screening out the rat with negative results of the APO erectile experiment and the behaviour-oriented experiment as the erectile dysfunction.
The compositions of example 1 and comparative examples 2 to 3 and the administration doses thereof, as well as the standard dose of the commercially available imazak tablet, were used to intervene in ED rats and a mating experiment was performed, with the intervention method being gavage once a day. Performing single-factor variance multiple-mean analysis on the back climbing times, the insertion times, the ejaculation times, the back climbing latency, the insertion latency and the ejaculation latency of ED rats after one week of intervention, and establishing a normal rat control group and an undried rat control group. The mating test results are shown in table 4:
table 4 mating test results of rats 1 week after intervention
Figure BDA0002448245870000111
Figure BDA0002448245870000112
In the context of Table 4, the following examples are,*for comparison with N groups, P<0.05；
△To compare P with ED group<0.05；
▲For comparison with the commercially available Italian Sack group P<0.05；
◆For comparison with AE group P<0.05。
As can be seen from table 4, after 1 week of intervention, the insertion latency and ejaculation latency were significantly reduced (P <0.05) in the example 1 group compared to the ED group; compared with the ED group, the rats in the comparative example 2 group, the comparative example 3 group, the example 1 group and the commercial Italian sago group have increased back climbing times, insertion times and ejaculation times, but have no significant difference (P > 0.05); compared with the ED group, the comparative example 2 group, the comparative example 3 group, the example 1 group and the commercial Italian sago group have reduced trend but no significant difference in back-climbing latency (P > 0.05). Compared with the ED group, the insertion latency and the ejaculation latency of the comparative example 2 group, the comparative example 3 group and the commercially available Italian sago group are reduced but have no significant difference (P > 0.05). Compared with the N group, the rat crawling back times, the inserting times and the ejaculation times of the ED group, the comparative example 2 group, the comparative example 3 group and the commercially available Italian sago group are obviously reduced (P < 0.05); the dorsalis crawling latency, the insertion latency and the ejaculation latency are obviously increased (P is less than 0.05); compared with the N groups, the rats in the group of example 1 have no significant difference in back climbing times, insertion times, ejaculation times, back climbing latency, insertion latency and ejaculation latency (P >0.05), and the rats in the group of example 1 are prompted to have improved sexual functions. The insertion and ejaculation latencies were significantly reduced in the example 1 group compared to the commercially available imazak group (P < 0.05); the group of example 1 had a significant reduction in crawling back latency (P <0.05) compared to the AE group; there were no significant differences between the remaining groups (P > 0.05).
The results of the mating experiments in ED rats after 2 weeks intervention are shown in table 5:
TABLE 5 mating test results in rats 2 weeks after intervention
Figure BDA0002448245870000121
Figure BDA0002448245870000122
In the context of Table 5, the following examples are given,*for comparison with N groups, P<0.05；
△To compare P with ED group<0.05；
▲Is a product of with commercial saleWood Sack group comparison P<0.05；
◆For comparison with AE group P<0.05。
As can be seen from table 5, after 2 weeks of intervention, there was a decrease in the climbing back latency of the comparative example 2 group, the comparative example 3 group, the example 1 group and the commercially available imazakhstan group compared to the ED group, but no significant difference (P > 0.05). Compared with the ED group, the insertion latency and the ejaculation latency of the comparative example 2 group, the comparative example 3 group and the commercially available Italian sago group are reduced but have no significant difference (P > 0.05). Compared with the N group, the frequency of crawling the back, the frequency of inserting and the frequency of ejaculation of the ED group rat are obviously reduced (P is less than 0.05); compared with the N group, the ED group rats have significantly increased dormitosis latency, insertion latency and ejaculation latency (P < 0.05). Compared with the N group, the number of ejaculation times of the rats in the comparative example 3 group is obviously reduced (P < 0.05); compared with the N group, the insertion times and ejaculation times of the commercially available Italian sago group are obviously reduced (P < 0.05); compared with the N groups, the rats in the example 1 group have no significant difference in back climbing times, insertion times and ejaculation times (P > 0.05). The COE group rats are suggested to have improved sexual function. Compared with the commercially available Italian Sack group, the insertion times of the comparative example 2 group, the comparative example 3 group and the example 1 group are increased, but the statistical difference is not generated (P > 0.05). The number of insertions was the most increased among the intervention groups compared to example 1, but there was no statistical difference (P > 0.05).
The results of the mating experiments in ED rats after 3 weeks of intervention are shown in table 6:
table 6 mating test results of rats 3 weeks after intervention
Figure BDA0002448245870000131
Figure BDA0002448245870000132
In the context of Table 6, the following examples are,*for comparison with N groups, P<0.05；
△To compare P with ED group<0.05；
▲For comparison with the commercially available Italian Sack group P<0.05；
◆Compared with the AE groupP<0.05。
As can be seen from table 6, after 3 weeks of intervention, the number of back-climbing, the number of insertions, and the number of ejaculation times of the rats in the comparative example 3 group, the example 1 group, and the imazakhstan group were significantly increased compared to the ED group (P < 0.05); insertion and ejaculation latencies were significantly reduced (P < 0.05). The description suggests that the comparative example 3 group, the example 1 group and the commercially available Italian saxophone tablet group all have certain therapeutic effects on the erectile dysfunction rats. Compared with the group N, the ED group has the advantages that the back climbing times, the insertion times and the ejaculation times are all obviously reduced (P is less than 0.05), and the back climbing latency, the insertion latency and the ejaculation latency are all obviously increased (P is less than 0.05); the ejaculation latency was significantly increased (P <0.05) in comparative example 2 compared to N; from the key index of the number of insertions, the therapeutic effects of the example 1, comparative 2 and comparative 3 groups were 92.41%, 35.56% and 87.76% of the commercially available imazakh group, respectively. The efficacy of the Isuzumab extract obtained in the present invention was substantially the same as that of the commercially available Isuzumab tablets.
As can be seen from the test examples, the Isuzumab extract prepared by the preparation method disclosed by the invention has definite active ingredients, and can effectively reduce the drug dosage on the basis of not influencing the drug effect.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.

Claims (10)

1. A preparation method of an Italian Saxak extract is characterized by comprising the following steps:
(1) mixing flos Caryophylli, rhizoma Bletillae, plantula Papaveris, semen Myristicae, Olibanum, semen Strychni, rhizoma Alpiniae Officinarum and stigma croci Sativi according to their prescription amount in IMUXACAKE, pulverizing, and sieving to obtain mixture powder;
(2) carrying out alcohol reflux extraction on the mixture powder to obtain an alcohol extract and alcohol extract dregs;
(3) sequentially carrying out first concentration, first freeze drying and second crushing and sieving on the alcohol extract to obtain alcohol extract powder;
(4) decocting the alcohol extract dregs in water to obtain water extract extractum and water extract dregs;
(5) sequentially carrying out second concentration, second freeze drying, third crushing and sieving on the water extract to obtain water extract powder;
(6) mixing the ethanol extract powder and the water extract powder with penis et testis bovis seu Bubali, Moschus, and ambergris to obtain an Italian Sak extract; the dosages of the bullwhip, the musk and the ambergris are the amounts of the bullwhip, the musk and the ambergris in the Italian saxophone;
the step (3) and the steps (4) and (5) have no requirement of time sequence.
2. The method according to claim 1, wherein the mixture powder has a particle size of 250 μm or less.
3. The preparation method according to claim 1, wherein the alcohol extracting agent used in the alcohol reflux extraction in the step (2) is an ethanol solution, and the volume fraction of the ethanol solution is 60%; the mass ratio of the mixture powder to the ethanol solution is 1: 8-10;
the temperature of the alcohol reflux extraction is 100-110 ℃; the reflux extraction times of the alcohol are 2-3 times; the time of single alcohol reflux extraction is 2-3 h.
4. The preparation method according to claim 1, wherein the first concentration in the step (3) is reduced pressure concentration, the pressure of the reduced pressure concentration is 0.085-0.095 MPa, and the time is 8-10 h;
the temperature of the first freeze drying is-40 ℃, and the time is 48-54 h;
the particle size of the alcohol extract powder is 150-250 mu m.
5. The preparation method according to claim 1, wherein the mass ratio of the alcohol extract residues to water in the water decoction in the step (4) is 1: 8-10; the boiling temperature is 95-100 ℃;
the number of times of water boiling is 2-3, and the time of single water boiling is 2-3 h.
6. The preparation method according to claim 1, wherein the second concentration in the step (5) is reduced pressure concentration, the pressure of the reduced pressure concentration is 0.085-0.095 MPa, and the time is 8-10 h;
the temperature of the second freeze drying is-40 ℃, and the time is 48-54 h;
the particle size of the water extract powder is less than or equal to 250 mu m.
7. The preparation method of claim 1, wherein the particle size of the bullwhip, the musk and the ambergris in the step (6) is independently less than or equal to 250 μm.
8. The Italian Saka extract prepared by the preparation method of any one of claims 1-7, wherein the active ingredients in the Italian Saka extract are total polysaccharides, total saponins, total alkaloids and total flavonoids.
9. The Italian saxak extract according to claim 8, wherein the total polysaccharide accounts for 25.74-26.26% of the Italian saxak extract by mass;
the mass percentage of the total saponins in the Isuzkak extract is 21.71-22.13%;
the mass percentage of the total alkaloids in the Isuzkake extract is 17.92-18.28%;
the mass percentage of the total flavone in the Isuzkak extract is 21.53-21.96%.
10. Use of an imazakhstan extract according to claim 8 or 9 for the preparation of an imazakhstan medicament.
CN202010285248.2A 2020-04-13 2020-04-13 Isuzkak extract and preparation method and application thereof Pending CN111329973A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010285248.2A CN111329973A (en) 2020-04-13 2020-04-13 Isuzkak extract and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010285248.2A CN111329973A (en) 2020-04-13 2020-04-13 Isuzkak extract and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN111329973A true CN111329973A (en) 2020-06-26

Family

ID=71175414

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010285248.2A Pending CN111329973A (en) 2020-04-13 2020-04-13 Isuzkak extract and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN111329973A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1358517A (en) * 2000-12-15 2002-07-17 新疆维吾尔自治区和田地区维吾尔医院 Yimusake table for preventing and treating male disease
CN106546754A (en) * 2016-12-09 2017-03-29 新疆医科大学 Yimusake table acts on abnormal mucus cross-examination with sexual impotence Syndrome model target point protein and its screening technique
CN109633175A (en) * 2019-01-09 2019-04-16 新疆医科大学 A kind of Yimusake table acts on the combination of Erectile Dysfunction human serum differential protein and its screening technique and application

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1358517A (en) * 2000-12-15 2002-07-17 新疆维吾尔自治区和田地区维吾尔医院 Yimusake table for preventing and treating male disease
CN106546754A (en) * 2016-12-09 2017-03-29 新疆医科大学 Yimusake table acts on abnormal mucus cross-examination with sexual impotence Syndrome model target point protein and its screening technique
CN109633175A (en) * 2019-01-09 2019-04-16 新疆医科大学 A kind of Yimusake table acts on the combination of Erectile Dysfunction human serum differential protein and its screening technique and application

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
戴德银等: "《新编简明中成药手册》", 31 December 2014, 人民军医出版社 *
翟欣等: "伊木萨克片定性定量研究", 《药物分析杂志》 *

Similar Documents

Publication Publication Date Title
CN103768152A (en) Osmanthus phenylethanoid glycoside extract, and preparation method and application thereof
CN104666373A (en) Novel use of Eurycoma longifolia Jack
WO2006063515A1 (en) Use of radix sanguisorbae and its extract for preparing medicament to increase rbc and hemoglobin
CN101849950A (en) Application of rotundic acid in preparing blood lipid regulating medicines
CN103566282B (en) A kind of Traditional Chinese medicine composition with anti-tumor effect and preparation method
CN101040891B (en) Method of preparing tripterygium hypoglaucum (Levl) hutch alkaloids
CN111329973A (en) Isuzkak extract and preparation method and application thereof
CN106535912B (en) Control pharmaceutical composition and its application of human body blood fat and body weight
JP7340113B2 (en) Chinese herbal composition and its production method and use
CN101204509B (en) Chinese traditional medicine soft capsule and preparation method thereof
CN101219200B (en) Traditional Chinese medicine soft capsule and preparing method thereof
CN102526387B (en) Medicinal composition for treating early-stage diabetic foot and preparation method thereof
CN101147767A (en) Medicinal composition for treating acne and its capsule preparation method
CN105535070B (en) The pharmaceutical composition and its preparation method and application for treating diabetes
CN100355440C (en) Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method
CN103142597B (en) Ipecacuanha effective component composition, its preparation method and application
CN110420264B (en) Traditional Chinese medicine composition and preparation method and application thereof
CN116350736B (en) Traditional Chinese medicine composition for preventing and treating breast nodules
CN112870282B (en) Areca catechu extract for improving gastric motility and preparation process and application thereof
CN115282212B (en) Jiujin capsule and preparation method and application thereof
CN118021750B (en) Preparation method of throat clearing capsule
CN113546116B (en) Preparation method of traditional Chinese medicine extract with blood pressure lowering effect
CN107469014A (en) A kind of pharmaceutical composition for treating female mammary gland proliferation disease and preparation method thereof
CN101391076A (en) Huidouba extract traditional Chinese medicine preparation for treating diabetes
CN101219201B (en) Traditional Chinese medicine liquid capsule and its preparing method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination